Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease

European Neurology

Volumn 39, Issue 2, 1998, Pages 119-124

  Dingemanse, J ^a   Kleinbloesem, C H ^a   Crevoisier, Ch ^b   Lankhaar, G ^a   Gasser, U E ^c  

^a Clin Pharma Research AG   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Roche Pharma Schweiz AG   (Switzerland)

Author keywords

Dual release; Food effect; Levodopa; Parkinson's disease; Pharmacokinetics; Tablet breaking

Indexed keywords

3 O METHYLDOPA; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; LEVODOPA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; MEAL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; FOOD; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE; TABLETS; TYROSINE;

EID: 0031891930     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007918     Document Type: Article

References (29)

1. Marsden CD: Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681.
2. Harder S, Baas H, Bergemann N, Demisch L, Rietbrock S: Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled-release formulation. Br J Clin Pharmacol 1995;39:39-44.
3. Nutt JG, Fellman JH: Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
4. LeWitt PA: Therapy with dopaminergic drugs in Parkinson's disease: in Koller WC (ed): Handbook of Parkinson's Disease, ed 2. New York, Dekker, 1992, pp 469-508.
5. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS: Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 1976;11:329-377.
6. Zürcher G, Da Prada M: Simple automated high-performance liquid Chromatographic column-switching technique for the measurement of dopa and 3-O-methyldopa in plasma. J Chromatogr Biomed Appl 1990;530:253-262.
7. Heinzel G, Woloszczak R, Thomann P: TopFit 2.0 Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Stuttgart, Fischer, 1993.
8. Gibaldi M, Perrier D: Pharmacokinetics, ed 2. New York, Dekker, 1982.
9. Diletti E, Hauske D, Steinijans VW: Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991;29:1-8.
10. Schuirmann DJ: A comparison of the two onesided tests procedure and power approach for assessing the equivalence and average bioavailability. J Pharmacokinet Biopharm 1987;15: 637-680.
11. Food and Drug Administration (FDA): Report by the bioequivalence task force on recommendation from the bioequivalence hearing conducted by the FDA, Sept 29 to Oct 1, 1986. Rockville, FDA, 1988.
12. Committee for Proprietary Medicinal Products (CPMP): Working Party on the Efficacy of Medicinal Products 1991. Note for guidance: Investigation of bioavailability and bioequivalence.
13. Crevoisier Ch, Hoevels B, Zürcher G, Da Prada M: Bioavailability of L-Dopa after Madopar® HBS administration in healthy volunteers. Eur Neurol 1987;27(suppl 1):36-46.
14. Gasser UE, Crevoisier Ch, Ouwerkerk M, Lankhaar G, Dingemanse J: Comparative single-and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. J Neurol, in press.
15. Ghika J, Gachoud JP, Gasser U and the L-Dopa Dual-Release Study Group: Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. Clin Neuropharmacol 1997;20:130-139.
16. Kuruma I, Bartholini G, Tissot R, Pletscher A: The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 1971;12:678-682.
17. Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, Smith ME, Titus DC: Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989;39(suppl 2):25-38.
18. Johnston BT, Li Q, Castell JA, Castell DO: Swallowing and esophageal function in Parkinson's disease. Am J Gastroenterol 1995;90: 1741-1746.
19. Grahnén A, Eckernäs SA, Collin C, Ling-Andersson A, Tiger G, Nilsson M: Comparative multiple-dose pharmacokinetics of slow-release levodopa products. Eur Neurol 1992;32: 343-348.
20. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, Van Brummelen P: Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
21. Robertson DRC, Renwick AG, Wood ND, Cross N, Macklin BS, Fleming JS, Waller DG, George CF: The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 1990;29:47-53.
22. Lennernäs H, Nilsson D, Aquilonius S-M, Ahrenstedt Ö, Knutson L, Paalzow LK: The effect of L-leucine on the absorption of levodopa. studied by regional jejunal perfusion in man. Br J Clin Pharmacol 1993;35:243-250.
23. Frankel JP, Kempster PA, Bovingdon M, Webster R, Lees AJ, Stern GM: The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 1989;52:1063-1067.
24. Robertson DRC, Higginson I, Macklin BS, Renwick AG, Waller DG, George CF: The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol 1991;31:413-417.
25. Morris JGL, Parsons RL, Trounce JR, Groves MJ: Plasma dopa concentrations after different preparations of levodopa in normal subjects. Br J Clin Pharmacol 1976;3:983-990.
26. Dempski RE, Scholtz EC, Oberholtzer ER, Yeh KC: Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 1989;39(suppl 2):20-24.
27. Andersson I, Granerus A-K, Jagenburg R, Svanborg A: Intestinal decarboxylation of orally administered L-dopa. Acta Med Scand 1975; 198:415-420.
28. Crevoisier Ch, Zürcher G, Ziegler WH: The influence of food on the pharmacokinetics of L-Dopa: A study with Madopar® HBS. New Trends Clin Neuropharmacol 1994;8:221.
29. Mizuno Y, Mori H, Kando T: Practical guidelines for the drug treatment of Parkinson's disease. CNS Drugs 1994;1:410-426.